var data={"title":"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/contributors\" class=\"contributor contributor_credentials\">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 29, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Failure of treatment for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) bacteremia with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> should prompt consideration of infection due to <em>S. aureus</em> with reduced susceptibility to vancomycin, either de novo or emergent.</p><p>Reduced <em>S. aureus</em> susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> may occur via increased vancomycin minimum inhibitory concentration (MIC; known as &quot;MIC creep&quot;), cell wall alterations (as in the case of vancomycin-intermediate <em>S. aureus</em> [VISA]), or plasmid-mediated gene transfer (as in the case of vancomycin-resistant <em>S. aureus</em> [VRSA]). (See <a href=\"#H1135065959\" class=\"local\">'Overview of mechanisms'</a> below.)</p><p>Issues related to the definitions, mechanism, epidemiology, and treatment of <em>S. aureus</em> bacteremia with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> will be reviewed here. Other issues related to <em>S. aureus</em> infection are discussed separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a> and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a> and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-prevention-and-control\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITIONS</span></p><p class=\"headingAnchor\" id=\"H3433302925\"><span class=\"h2\">MIC breakpoints</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Clinical and Laboratory Standards Institute (CLSI) and the US Food and Drug Administration (FDA) have established the following <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> minimum inhibitory concentration (MIC) interpretive criteria for <em>S. aureus</em>. The definitions were modified in response to increasing reports of vancomycin treatment failure in infections due to strains with elevated MICs (2 <span class=\"nowrap\">mcg/mL)</span> as well as to flag those isolates that are likely to be heteroresistant; the definitions prior to 2006 are noted in parentheses [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/1-3\" class=\"abstract_t\">1-3</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> susceptible: &le;2 <span class=\"nowrap\">mcg/mL</span> (&le;4 <span class=\"nowrap\">mcg/mL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> intermediate: 4 to 8 <span class=\"nowrap\">mcg/mL</span> (8 to 16 <span class=\"nowrap\">mcg/mL)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> resistant: &ge;16 <span class=\"nowrap\">mcg/mL</span> (&ge;32 <span class=\"nowrap\">mcg/mL)</span></p><p/><p>The acronyms for vancomycin-intermediate <em>S. aureus</em> (VISA), glycopeptide-intermediate <em>S. aureus</em> (GISA), and vancomycin-resistant <em>S. aureus</em> (VRSA) are derived from these criteria. VISA and GISA refer to the same susceptibility cutoff. The term VISA is more commonly used, although the term GISA may be more accurate since early reports indicated that most of these strains also had intermediate resistance to the glycopeptide teicoplanin.</p><p>In the face of appropriate source control, repeated isolation of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy for longer than three to four days should prompt consideration of infection with a strain of <em>S. aureus</em> with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> that has emerged during therapy, even if the MIC of the original isolate was within the susceptible range [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3-11\" class=\"abstract_t\">3-11</a>]; alternatively, persistent bacteremia may reflect abscess or metastatic infection rather than reduced antibiotic susceptibility. Others have defined persistent bacteremia as a positive blood culture result &gt;7 days after initiation of vancomycin therapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/9,12\" class=\"abstract_t\">9,12</a>]; however, data suggest that the longer methicillin-resistant <em>S. aureus </em>(MRSA) bacteremia persists, the greater the risk of complications [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia#H2810885724\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;, section on 'Adjustments to therapy'</a>.)</p><p>Reduced <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> susceptibility can occur in <em>S. aureus</em> irrespective of background methicillin susceptibility and may result in increased tolerance to several classes of antibiotics [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/13,14\" class=\"abstract_t\">13,14</a>]. (See <a href=\"#H11\" class=\"local\">'Treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H67468403\"><span class=\"h2\">Heteroresistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Heteroresistant vancomycin-intermediate <em>S. aureus</em> (hVISA) refers to VISA strains in which subpopulations display variable rather than uniform susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Heteroresistant strains of <em>S. aureus</em> contain subpopulations of bacteria with vancomycin MICs in the intermediate range, but the vancomycin MIC for the entire population of the strain remains within the susceptible range [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/16\" class=\"abstract_t\">16</a>]. Like VISA strains, hVISA populations have accumulated mutations that help withstand vancomycin by means of an unusually thickened cell wall. (See <a href=\"#H1135065959\" class=\"local\">'Overview of mechanisms'</a> below and <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p>The prototype heteroresistant strain was <em>S. aureus</em> Mu3, a clinical isolate recovered from a Japanese patient with staphylococcal pneumonia [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/16\" class=\"abstract_t\">16</a>]. The reported frequency of heteroresistance is variable. Most studies describe a frequency of 0.5 to 1.5 percent, but frequencies as high as 20 percent have been reported in Japan [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3,16,17\" class=\"abstract_t\">3,16,17</a>].</p><p>It is uncertain whether heteroresistance is a cause of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> treatment failure [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/18-20\" class=\"abstract_t\">18-20</a>]. However, there are several reports of vancomycin failure and persistent infection due to hVISA [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/21-23\" class=\"abstract_t\">21-23</a>]. In a review of 65 patients with endocarditis due to MRSA, 19 isolates (29 percent) exhibited the hVISA phenotype by population analysis profiling [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/23,24\" class=\"abstract_t\">23,24</a>]. Patients with these isolates were more likely to have persistent bacteremia (68 versus 37 percent) and heart failure (47 versus 19 percent) [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H1135065959\"><span class=\"h1\">OVERVIEW OF MECHANISMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reduced <em>S. aureus</em> susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> can occur via the following mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increase in the minimum inhibitory concentration (MIC) of methicillin-resistant <em>S. aureus</em> (MRSA) isolates to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> (known as &quot;MIC creep&quot;) &ndash; While these isolates have not necessarily reached the level of vancomycin resistance as vancomycin-intermediate <em>S. aureus</em> (VISA), they have been at the upper limits of the susceptibility range. This has raised concern regarding the efficacy of vancomycin for treatment of clinical infections caused by these organisms [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/2,25\" class=\"abstract_t\">2,25</a>]. (See <a href=\"#H1979104799\" class=\"local\">'Borderline vancomycin susceptibility'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vancomycin-intermediate <em>S. aureus</em> &ndash; The first clinical VISA isolate, described in 1997, was noted to have an unusually thickened cell wall containing excessive <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> target dipeptides (D-Ala-D-Ala) capable of &quot;trapping&quot; vancomycin, thereby reducing availability of the drug for cellular targets [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/15,26-35\" class=\"abstract_t\">15,26-35</a>]. (See <a href=\"#H2850130699\" class=\"local\">'Vancomycin-intermediate S. aureus'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vancomycin-resistant <em>S. aureus</em> (VRSA) &ndash; The first clinical VRSA isolate, described in 2002, emerged via <em>vanA</em> gene plasmid-mediated transfer from enterococci with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> resistance to <em>S. aureus</em> via mobile genetic element Tn1546 (similar to mechanism of vancomycin-resistant enterococci [VRE] emergence) [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/36-40\" class=\"abstract_t\">36-40</a>]. (See <a href=\"#H4069668302\" class=\"local\">'Vancomycin-resistant S. aureus'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H1979104799\"><span class=\"h2\">Borderline vancomycin susceptibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to borderline <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> susceptibility are discussed further separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia#H2406416818\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;, section on 'Borderline vancomycin susceptibility'</a>.)</p><p class=\"headingAnchor\" id=\"H2850130699\"><span class=\"h2\">Vancomycin-intermediate S. aureus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The genetic basis for cell wall alterations involves multiple mutations in genes contributing to cell wall synthesis. Several studies have identified mutations in selected genes, including <em>vraR</em>, <em>graRS</em>, and <em>walRK</em>, that appear to contribute to cell wall synthesis and, as a result, to the development of resistance [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/41-44\" class=\"abstract_t\">41-44</a>]. Downregulated genes also reduce expression of autolysins reducing cross-linking and autolysis [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/45,46\" class=\"abstract_t\">45,46</a>]. The group II polymorphism at the accessory gene regulator (agr) locus is present in some VISA strains (as well as some MRSA strains) [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/35,47\" class=\"abstract_t\">35,47</a>]. The increased metabolic demand caused by these thickened cell walls places these strains at a fitness disadvantage and may in part explain the limited instances of nosocomial spread of these strains in healthcare settings.</p><p>VISA strains often develop from MRSA strains that are exposed to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>; this was suggested by the similarity between pulse-field gel electrophoresis patterns of the MRSA and subsequent VISA strains isolated from individual patients [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/16,48-52\" class=\"abstract_t\">16,48-52</a>]. This course of events may have resulted from failure to eradicate the initial MRSA strain or subsequent reinfection with the same strain.</p><p>The colonial morphology of VISA strains may be different (eg, smaller or with different pigmentation) in part due to their slower growth rate [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"#H10\" class=\"local\">'Diagnosis and laboratory testing'</a> below.)</p><p class=\"headingAnchor\" id=\"H4069668302\"><span class=\"h2\">Vancomycin-resistant S. aureus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of different plasmids have been identified that are capable of transferring the Tn1546 transposon, including those containing both enterococcal and staphylococcal plasmid DNA [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/53\" class=\"abstract_t\">53</a>]. Resistance in VRSA isolates is due to the synthesis of an alternative cell wall terminal peptide (D-ala-D-lac) rather than the normal terminal peptide (D-ala-D-ala). <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is unable to bind to the former peptide. Expression of the <em>vanA</em> genes is only initiated by exposure to vancomycin so that there is limited effect on the fitness of the isolate (in contrast with the VISA strains).</p><p class=\"headingAnchor\" id=\"H1593593876\"><span class=\"h1\">EPIDEMIOLOGY</span></p><p class=\"headingAnchor\" id=\"H1509092719\"><span class=\"h2\">VISA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several vancomycin-intermediate <em>S. aureus</em> (VISA) strains associated with clinical infection have been described [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/15,18,48-52,54\" class=\"abstract_t\">15,18,48-52,54</a>]. The first reported case was observed in 1997 in Japan and occurred in a four-month-old with a surgical site infection. This original VISA strain was designated Mu50; its <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> minimum inhibitory concentration (MIC) was 8 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/15\" class=\"abstract_t\">15</a>]. The patient was successfully treated with <a href=\"topic.htm?path=amoxicillin-and-clavulanate-drug-information\" class=\"drug drug_general\">amoxicillin-clavulanate</a> plus <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>. However, the first infection with VISA appears to have occurred in 1995 in France in a two-year-old with leukemia and central catheter&ndash;associated bacteremia; management was successful with surgical drainage and <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/54\" class=\"abstract_t\">54</a>].</p><p>Subsequently, clinical infections with similar strains have been reported in the United States and around the world [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/18,48-51,55-57\" class=\"abstract_t\">18,48-51,55-57</a>]. Features common to many of the United States cases included ongoing or recent dialysis, methicillin-resistant <em>S. aureus </em>(MRSA) bacteremia associated with central venous catheters or prosthetic graft material, and prolonged <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> exposure (6 to 18 weeks) in the three to six months preceding infection [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/48,50-52\" class=\"abstract_t\">48,50-52</a>]. Contact investigation for two patients with VISA infection (including 177 contacts) yielded no VISA carriers [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/48\" class=\"abstract_t\">48</a>].</p><p>In general, the incidence of VISA is difficult to estimate given the rarity of infection and challenges related to laboratory detection. Surveillance data from the United States and Europe indicate that <em>S. aureus</em> isolates with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MICs &ge;4 <span class=\"nowrap\">mcg/mL</span> represent less than 0.3 percent of MIC values [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H408891732\"><span class=\"h2\">VRSA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been scattered reports of infection due to vancomycin-resistant <em>S. aureus</em> (VRSA) around the world.</p><p>In the United States, at least 14 cases have been identified [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/53,58-65\" class=\"abstract_t\">53,58-65</a>]. The first United States case of VRSA was reported in 2002, isolated from a newly infected chronic foot ulcer in a patient in Michigan with diabetes, peripheral artery disease, and chronic renal failure on hemodialysis [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/36\" class=\"abstract_t\">36</a>]. A strain of vancomycin-resistant <em>Enterococcus faecalis </em>(VRE) was also cultured from the ulcer, and DNA sequencing demonstrated that the <em>vanA</em> genes in the <em>Staphylococcus </em>and <em>Enterococcus </em>isolates were identical [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Additional cases were subsequently identified in Michigan as well as in Pennsylvania, New York, and Delaware. Most of the VRSA isolates were from skin and soft tissue sites, and the majority of case patients were also colonized or infected with a VRE [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/64\" class=\"abstract_t\">64</a>]. A comparative genomic analysis of the first 12 reported VRSA isolates concluded that resistance did not appear to be due to clonal dissemination of a single VRSA strain but rather represented separate events in which the plasmid containing the vancomycin-resistant transposon was acquired [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/53\" class=\"abstract_t\">53</a>].</p><p>Sporadic cases have been reported elsewhere. The first case in Europe was reported in 2013 [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/66\" class=\"abstract_t\">66</a>]. In 2014, a VRSA bloodstream infection caused by the epidemic, community-associated MRSA strain ST8 was reported in a young man in Brazil with diabetes who received several courses of antibiotics, including <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, for skin infections [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/67\" class=\"abstract_t\">67</a>]. VRSA was subsequently isolated during teicoplanin therapy for a methicillin-resistant but vancomycin-susceptible <em>S. aureus</em> bacteremia. Genomic analysis demonstrated that the <em>vanA</em> sequence in the VRSA was identical to that in a VRE isolate subsequently recovered from a rectal swab.</p><p>Because co-colonization with MRSA and VRE is common, development of further VRSA strains is likely [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Although the majority of VRSA isolates reported to date have been from healthcare-associated MRSA strains, a few have been associated with community-acquired strains (as noted above for the bloodstream VRSA infection from Brazil), indicating the possibility of transferring plasmid-mediated <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> resistance to various MRSA strains.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS AND LABORATORY TESTING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Failure of treatment for methicillin-resistant <em>S. aureus</em> (MRSA) bacteremia with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> should prompt consideration of infection due to <em>S. aureus</em> with reduced susceptibility to vancomycin, even if the minimum inhibitory concentration (MIC) is within the susceptible range [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3-6\" class=\"abstract_t\">3-6</a>].</p><p>Confirmatory MIC testing should be performed on <em>S. aureus</em> isolates for which the <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC is &ge;2 <span class=\"nowrap\">mcg/mL</span>. Laboratory detection of <em>S. aureus </em>with reduced susceptibility to vancomycin may require special inquiry with the microbiology laboratory about susceptibility testing methods as discussed below [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/70\" class=\"abstract_t\">70</a>].</p><p>An MIC susceptibility testing method (such as broth microdilution, agar dilution, or agar-gradient diffusion [E-test]) must be used for detection of <em>S. aureus</em> with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>; disk diffusion or automated methods are not sufficient [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/71-74\" class=\"abstract_t\">71-74</a>]. E-tests generally yield results that are one tube dilution higher than other methods [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/2\" class=\"abstract_t\">2</a>]. A full 24-hour incubation period should be used with all methods. The use of matrix-assisted laser <span class=\"nowrap\">desorption/ionization</span> time of flight mass spectrometry (MALDI-TOF MS) to distinguish vancomycin-susceptible <em>S. aureus </em>(VSSA) from vancomycin-intermediate <em>S. aureus </em>(VISA) suggests that this newer technology may soon be able to rapidly detect these strains with reduced susceptibility to vancomycin [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/75\" class=\"abstract_t\">75</a>].</p><p>The approach to <em>S. aureus</em> susceptibility testing should be tailored to the clinical scope of a particular laboratory [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/57,76\" class=\"abstract_t\">57,76</a>]. Additional susceptibility testing is warranted in patients with repeated isolates of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy for longer than three to four days. Isolates should also be sent to the state public health laboratory or the United States Centers for Disease Control and Prevention for confirmatory evaluation when <em>S. aureus</em> with reduced susceptibility is suspected. (See <a href=\"#H3433302925\" class=\"local\">'MIC breakpoints'</a> above.)</p><p>There is no validated laboratory test for routine detection of heteroresistant <em>S. aureus</em> populations; a number of methods have been described. The most accurate method consists of performing population analysis profiles [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/24\" class=\"abstract_t\">24</a>]. As a result of this uncertainty, the Clinical and Laboratory Standards Institute (CLSI) lowered the intermediate <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC breakpoint to 4 <span class=\"nowrap\">mcg/mL</span> in order to flag isolates that are likely to be heteroresistant <span class=\"nowrap\">and/or</span> clinically refractory to vancomycin therapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"#H67468403\" class=\"local\">'Heteroresistance'</a> above and <a href=\"#H3433302925\" class=\"local\">'MIC breakpoints'</a> above and <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>General issues related to evaluation and management of <em>S. aureus</em> bacteremia and the duration of antibiotic therapy (which depends on the source of infection) are discussed separately. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a>.)</p><p>General issues related to treatment of methicillin-resistant <em>S. aureus </em>(MRSA) infection are discussed separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2427921132\"><span class=\"h2\">Clinical approach</span></p><p class=\"headingAnchor\" id=\"H504937060\"><span class=\"h3\">Borderline vancomycin susceptibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with infection due to <em>S. aureus</em> isolates approaching the limit of the susceptible range (2 <span class=\"nowrap\">mcg/mL)</span> who are not responsive to or are intolerant of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, there are several potential alternative agents. The approach is discussed further separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia#H2406416818\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;, section on 'Borderline vancomycin susceptibility'</a>.)</p><p class=\"headingAnchor\" id=\"H3869691427\"><span class=\"h3\">Infection due to VISA or VRSA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal regimen for treatment of infection due to vancomycin-intermediate <em>S. aureus </em>(VISA) or vancomycin-resistant <em>S. aureus </em>(VRSA) infection is uncertain.</p><p>Monotherapy is reasonable for patients with bacteremia and proven absence of deep-seated infection. Combination therapy is warranted for patients with bacteremia and concomitant deep-seated infection to minimize the likelihood of emergence of resistance during therapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/11,77,78\" class=\"abstract_t\">11,77,78</a>]. It has been observed that treatment of serious VISA infection with <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> monotherapy may increase the risk for emergence of resistance during therapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/79\" class=\"abstract_t\">79</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible combination regimens include [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/11\" class=\"abstract_t\">11</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> plus <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> or other beta-lactams [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/80-84\" class=\"abstract_t\">80-84</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> plus <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> or other beta-lactams [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/85,86\" class=\"abstract_t\">85,86</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">Daptomycin</a> plus <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/87\" class=\"abstract_t\">87</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">Ceftaroline</a> plus <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/88\" class=\"abstract_t\">88</a>]</p><p/><p class=\"bulletIndent1\">Based on the available data, we favor combination therapy with <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (dosed at 8 to 10 <span class=\"nowrap\">mg/kg</span> rather than 6 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily) and <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/80,83\" class=\"abstract_t\">80,83</a>]. This approach is based on a small case series that included 26 patients whose MRSA isolates had diminished daptomycin susceptibility; after persistent bacteremia for a median of 10 days on previous antimicrobial therapy, the median time to clearance of bacteremia was two days [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/83\" class=\"abstract_t\">83</a>]. Another report noted enhanced bactericidal activity in vitro with combination therapy using daptomycin and ceftaroline [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/81\" class=\"abstract_t\">81</a>]. Use of this regimen may be limited by cost.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Possible monotherapy regimens include <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a>, <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a>, and <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/89-93\" class=\"abstract_t\">89-93</a>]. Telavancin monotherapy may prove effective for treatment of MRSA bacteremia (thus far, available data largely reflects study of pneumonia); in a phase II trial of telavancin for treatment of bacteremia including 17 patients, cure rates were comparable for telavancin and standard therapy (88 versus 89 percent) [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/91,94\" class=\"abstract_t\">91,94</a>]. </p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=dalbavancin-drug-information\" class=\"drug drug_general\">Dalbavancin</a> and <a href=\"topic.htm?path=oritavancin-drug-information\" class=\"drug drug_general\">oritavancin</a> are long-acting lipoglycopeptides; data on these agents for the treatment of MRSA bacteremia are limited as are data on <a href=\"topic.htm?path=ceftaroline-drug-information\" class=\"drug drug_general\">ceftaroline</a> monotherapy [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/83,89\" class=\"abstract_t\">83,89</a>]. <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid</a> and <a href=\"topic.htm?path=tedizolid-drug-information\" class=\"drug drug_general\">tedizolid</a> are bacteriostatic (<a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, ceftaroline, and <a href=\"topic.htm?path=telavancin-drug-information\" class=\"drug drug_general\">telavancin</a> are bactericidal), and toxicity limits prolonged use [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/90\" class=\"abstract_t\">90</a>].</p><p/><p>There is no role for use of <a href=\"topic.htm?path=quinupristin-and-dalfopristin-drug-information\" class=\"drug drug_general\">quinupristin-dalfopristin</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, or fluoroquinolones for treatment of <em>S. aureus</em> bacteremia.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Special efforts to ensure compliance with contact precautions and handwashing should be instituted when patients are infected or colonized with <em>S. aureus</em> strains with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/95,96\" class=\"abstract_t\">95,96</a>]. Issues related to nasal decolonization and <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> bathing for prevention of <em>S. aureus </em>infection are discussed further separately. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-prevention-and-control\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control&quot;</a>.)</p><p>In addition, healthcare providers should be vigilant about removing temporary venous catheters when they are no longer needed and minimizing prolonged empiric antimicrobial therapy whenever possible [<a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/6,97\" class=\"abstract_t\">6,97</a>].</p><p>Consultation with infectious disease specialists, hospital epidemiologists, the local health department, and the United States Centers for Disease Control and Prevention is appropriate for optimizing laboratory investigation, patient management, and infection control issues. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Failure of treatment for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) bacteremia with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> should prompt consideration of infection due to <em>S. aureus</em> with reduced susceptibility to vancomycin, even if the minimum inhibitory concentration (MIC) is within the susceptible range. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced <em>S. aureus</em> susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> may occur via increased vancomycin MIC (known as &quot;MIC creep&quot;), cell wall alterations (as in the case of vancomycin-intermediate <em>S. aureus</em> [VISA]), or plasmid-mediated gene transfer (as in the case of vancomycin-resistant <em>S. aureus</em> [VRSA]). (See <a href=\"#H1135065959\" class=\"local\">'Overview of mechanisms'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Clinical and Laboratory Standards Institute (CLSI) definitions for <em>S. aureus</em> <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> minimal inhibitory concentrations are as follows (see <a href=\"#H3433302925\" class=\"local\">'MIC breakpoints'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> susceptible: &le;2 <span class=\"nowrap\">mcg/mL</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> intermediate: 4 to 8 <span class=\"nowrap\">mcg/mL</span></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> resistant: &ge;16 <span class=\"nowrap\">mcg/mL</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heteroresistant strains of <em>S. aureus</em> contain subpopulations of bacteria with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MICs in the intermediate range, but the vancomycin MIC for the entire population of the strain is within the susceptible range. There is no validated laboratory test for routine detection of heteroresistant <em>S. aureus</em> populations. (See <a href=\"#H67468403\" class=\"local\">'Heteroresistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An MIC susceptibility testing method (such as broth microdilution, agar dilution, or agar-gradient diffusion) must be used for detection of <em>S. aureus</em> with reduced susceptibility to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>; disk diffusion or automated methods are not sufficient. (See <a href=\"#H10\" class=\"local\">'Diagnosis and laboratory testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The optimal regimen for infection due to VISA or VRSA is uncertain; potential regimens are discussed above. (See <a href=\"#H3869691427\" class=\"local\">'Infection due to VISA or VRSA'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/1\" class=\"nounderline abstract_t\">Soriano A, Marco F, Mart&iacute;nez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193.</a></li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. M100-S16 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard. Vol 26. No 3. CLSI, Wayne, PA 2006.</li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/3\" class=\"nounderline abstract_t\">Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/4\" class=\"nounderline abstract_t\">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/5\" class=\"nounderline abstract_t\">Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/6\" class=\"nounderline abstract_t\">Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48:4926.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/7\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/8\" class=\"nounderline abstract_t\">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/9\" class=\"nounderline abstract_t\">Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/10\" class=\"nounderline abstract_t\">Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014; 59:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/11\" class=\"nounderline abstract_t\">Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 2016; 71:576.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/12\" class=\"nounderline abstract_t\">Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190:1140.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/13\" class=\"nounderline abstract_t\">Pillai SK, Wennersten C, Venkataraman L, et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009; 49:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/14\" class=\"nounderline abstract_t\">Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/15\" class=\"nounderline abstract_t\">Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/16\" class=\"nounderline abstract_t\">Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/17\" class=\"nounderline abstract_t\">Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29:760.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/18\" class=\"nounderline abstract_t\">Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/19\" class=\"nounderline abstract_t\">R&oslash;der BL, Wandall DA, Frimodt-M&oslash;ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/20\" class=\"nounderline abstract_t\">Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51 Suppl 2:S183.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/21\" class=\"nounderline abstract_t\">Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/22\" class=\"nounderline abstract_t\">Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/23\" class=\"nounderline abstract_t\">Bae IG, Federspiel JJ, Mir&oacute; JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/24\" class=\"nounderline abstract_t\">Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47:399.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/25\" class=\"nounderline abstract_t\">Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/26\" class=\"nounderline abstract_t\">Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/27\" class=\"nounderline abstract_t\">Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1:57.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/28\" class=\"nounderline abstract_t\">Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41:5.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/29\" class=\"nounderline abstract_t\">Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/30\" class=\"nounderline abstract_t\">Cui L, Iwamoto A, Lian JQ, et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:428.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/31\" class=\"nounderline abstract_t\">Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/32\" class=\"nounderline abstract_t\">Cui L, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44:2276.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/33\" class=\"nounderline abstract_t\">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/34\" class=\"nounderline abstract_t\">Howden BP, Johnson PD, Ward PB, et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:3039.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/35\" class=\"nounderline abstract_t\">Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/36\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/37\" class=\"nounderline abstract_t\">Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/38\" class=\"nounderline abstract_t\">Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72:195.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/39\" class=\"nounderline abstract_t\">Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005; 49:470.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/40\" class=\"nounderline abstract_t\">Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 Suppl 1:S25.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/41\" class=\"nounderline abstract_t\">Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 2007; 104:9451.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/42\" class=\"nounderline abstract_t\">Howden BP, Stinear TP, Allen DL, et al. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:3755.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/43\" class=\"nounderline abstract_t\">Howden BP, McEvoy CR, Allen DL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7:e1002359.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/44\" class=\"nounderline abstract_t\">Shoji M, Cui L, Iizuka R, et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55:3870.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/45\" class=\"nounderline abstract_t\">Hu Q, Peng H, Rao X. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus. Front Microbiol 2016; 7:1601.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/46\" class=\"nounderline abstract_t\">Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol 2014; 21:575.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/47\" class=\"nounderline abstract_t\">Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/48\" class=\"nounderline abstract_t\">Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/49\" class=\"nounderline abstract_t\">Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/50\" class=\"nounderline abstract_t\">Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340:517.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/51\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/52\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/53\" class=\"nounderline abstract_t\">Kos VN, Desjardins CA, Griggs A, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio 2012; 3.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/54\" class=\"nounderline abstract_t\">Ploy MC, Gr&eacute;laud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/55\" class=\"nounderline abstract_t\">Oliveira GA, Dell'Aquila AM, Masiero RL, et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 2001; 22:443.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/56\" class=\"nounderline abstract_t\">Kim MN, Pai CH, Woo JH, et al. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38:3879.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/57\" class=\"nounderline abstract_t\">Hubert SK, Mohammed JM, Fridkin SK, et al. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999; 37:3590.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/58\" class=\"nounderline abstract_t\">Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/59\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/60\" class=\"nounderline abstract_t\">Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/61\" class=\"nounderline abstract_t\">Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/62\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus--New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/63\" class=\"nounderline abstract_t\">Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/64\" class=\"nounderline abstract_t\">Limbago BM, Kallen AJ, Zhu W, et al. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol 2014; 52:998.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/65\" class=\"nounderline abstract_t\">Walters MS, Eggers P, Albrecht V, et al. Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1056.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/66\" class=\"nounderline abstract_t\">Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013; 382:205.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/67\" class=\"nounderline abstract_t\">Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014; 370:1524.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/68\" class=\"nounderline abstract_t\">Furuno JP, Perencevich EN, Johnson JA, et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization. Emerg Infect Dis 2005; 11:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/69\" class=\"nounderline abstract_t\">Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008; 46:675.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/70\" class=\"nounderline abstract_t\">Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009; 47:2013.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/71\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Laboratory capacity to detect antimicrobial resistance, 1998. MMWR Morb Mortal Wkly Rep 2000; 48:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/72\" class=\"nounderline abstract_t\">Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/73\" class=\"nounderline abstract_t\">Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/74\" class=\"nounderline abstract_t\">Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39:539.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/75\" class=\"nounderline abstract_t\">Mather CA, Werth BJ, Sivagnanam S, et al. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J Clin Microbiol 2016; 54:883.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention: Healthcare-associated Infections (HAI) http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_algo.html (Accessed on August 20, 2009).</li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/77\" class=\"nounderline abstract_t\">Holubar M, Meng L, Deresinski S. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches. Infect Dis Clin North Am 2016; 30:491.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/78\" class=\"nounderline abstract_t\">Nigo M, Diaz L, Carvajal LP, et al. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/79\" class=\"nounderline abstract_t\">Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66:1057.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/80\" class=\"nounderline abstract_t\">Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/81\" class=\"nounderline abstract_t\">Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57:66.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/82\" class=\"nounderline abstract_t\">Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother 2015; 70:505.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/83\" class=\"nounderline abstract_t\">Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/84\" class=\"nounderline abstract_t\">Mehta S, Singh C, Plata KB, et al. &beta;-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56:6192.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/85\" class=\"nounderline abstract_t\">Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother 2015; 70:311.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/86\" class=\"nounderline abstract_t\">Davis JS, Sud A, O'Sullivan MV, et al. Combination of Vancomycin and &beta;-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin Infect Dis 2016; 62:173.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/87\" class=\"nounderline abstract_t\">Claeys KC, Smith JR, Casapao AM, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2015; 59:1969.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/88\" class=\"nounderline abstract_t\">Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis 2014; 1:ofu046.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/89\" class=\"nounderline abstract_t\">Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013; 42:450.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/90\" class=\"nounderline abstract_t\">Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49:395.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/91\" class=\"nounderline abstract_t\">Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 2015; 60:787.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/92\" class=\"nounderline abstract_t\">Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010; 54:5376.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/93\" class=\"nounderline abstract_t\">Balkhair A, Al Muharrmi Z, Darwish L, et al. Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid. Int J Infect Dis 2010; 14 Suppl 3:e227.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/94\" class=\"nounderline abstract_t\">Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/95\" class=\"nounderline abstract_t\">de Lassence A, Hidri N, Timsit JF, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006; 42:170.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/96\" class=\"nounderline abstract_t\">Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27:245.</a></li><li><a href=\"https://www.uptodate.com/contents/staphylococcus-aureus-bacteremia-with-reduced-susceptibility-to-vancomycin/abstract/97\" class=\"nounderline abstract_t\">Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996; 17:356.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3165 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITIONS</a><ul><li><a href=\"#H3433302925\" id=\"outline-link-H3433302925\">MIC breakpoints</a></li><li><a href=\"#H67468403\" id=\"outline-link-H67468403\">Heteroresistance</a></li></ul></li><li><a href=\"#H1135065959\" id=\"outline-link-H1135065959\">OVERVIEW OF MECHANISMS</a><ul><li><a href=\"#H1979104799\" id=\"outline-link-H1979104799\">Borderline vancomycin susceptibility</a></li><li><a href=\"#H2850130699\" id=\"outline-link-H2850130699\">Vancomycin-intermediate S. aureus</a></li><li><a href=\"#H4069668302\" id=\"outline-link-H4069668302\">Vancomycin-resistant S. aureus</a></li></ul></li><li><a href=\"#H1593593876\" id=\"outline-link-H1593593876\">EPIDEMIOLOGY</a><ul><li><a href=\"#H1509092719\" id=\"outline-link-H1509092719\">VISA</a></li><li><a href=\"#H408891732\" id=\"outline-link-H408891732\">VRSA</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS AND LABORATORY TESTING</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">TREATMENT</a><ul><li><a href=\"#H2427921132\" id=\"outline-link-H2427921132\">Clinical approach</a><ul><li><a href=\"#H504937060\" id=\"outline-link-H504937060\">- Borderline vancomycin susceptibility</a></li><li><a href=\"#H3869691427\" id=\"outline-link-H3869691427\">- Infection due to VISA or VRSA</a></li></ul></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">PREVENTION</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">Clinical approach to Staphylococcus aureus bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-prevention-and-control\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing\" class=\"medical medical_review\">Overview of antibacterial susceptibility testing</a></li></ul></div></div>","javascript":null}